

Company Overview

BIONIK is a global pioneering healthcare company on a mission to supply quality-of-life solutions to those with movement impairments. Our goal is to enable the growing millions of people with movement-impairments to lead fuller and more independent lives by fostering hope, recovery and independence with evidence-based technologies, spanning the continuum of rehabilitation care.

The Company's product portfolio includes three InMotion® Robots for rehabilitation following stroke and other neurological conditions and four products in varying stages of development. Resulting from groundbreaking research at the Newman Laboratory for Biomechanics and Human Rehabilitation at the Massachusetts Institute of Technology (MIT), the InMotion® Robots provide effective, patient-adaptive therapy, intended to restore upper-extremity motor control for a broad range of neurological conditions and recovery stages, including early recovery from acute stroke.

The InMotion® Robots also provide objective evaluation assessments intended to measure and report the patient's level of motor impairment and progress during the course of therapy. A home version of the InMotion® upper-extremity technology is in development, as well as a wearable, lower-extremity, assistive product based on the company's ARKE exoskeleton technology. Targeted for the consumer market, the ARKE-based assistive device is intended to help certain individuals walk better.

Bionik Laboratories Granted United States Patent for Innovative Rehabilitation Technology

Sep 14 2023, 7:30 AM EDT

Stock Overview		Investor Relations
Symbol	BNKL	Richard Russo, Jr., CPA
Exchange	OTCQB	Chief Financial Officer
Market Cap		rrusso@bioniklabs.com
Last Price	\$	
52-Week	\$ - \$	

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

Management Team

Richard Russo, Jr., CPA

Chief Executive Officer; President

Dan Gonsalves, CPA

Corporate Controller

Mark Eiseman

Sales Director

John Smathers

Director of Operations

BIONIK Laboratories Corp.

80 Coolidge Hill Road

Watertown, MA 02472